Copyright © 2014 University of York.
Bookshelf ID: NBK82756
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet]. York (UK): Centre for Reviews and Dissemination (UK); 1995-.
Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet].
Show detailsBibliographic details: Dold M, Aigner M, Lanzenberger R, Kasper S. Efficacy of antipsychotic augmentation therapy in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomised, placebo-controlled trials. [Effektivitat einer Augmentationstherapie mit Antipsychotika bei therapieresistenten Zwangsstorungen: eine Metaanalyse doppelblinder, randomisierter, placebokontrollierter Studien.] Fortschritte der Neurologie - Psychiatrie 2011; 79(8): 453-466. [PubMed: 21809258]
Abstract
Only 40 - 60 % of all patients with obsessive-compulsive disorder (OCD) respond to serotonin reuptake inhibitors (SRIs). Therefore, the evaluation of additive treatment in the presence of treatment resistance has high clinical relevance. All double-blind, randomised, placebo-controlled trials that evaluated the efficacy of a combination therapy of SRIs and antipsychotics in treatment-resistant OCD were identified by systematic literature searches and combined in a meta-analysis. 11 studies with a total of 356 treatment-resistant patients were included. After the augmentation, significantly more subjects in the intervention groups (SRI + antipsychotic) fulfilled the response criterion (reduction in the Yale-Brown obsessive compulsive scale [Y-BOCS] ≥ 35 %) than in the control groups (SRI + placebo) (relative risk = 2.16). The subgroup analysis showed significant efficacy only for risperidone. Further significant differences have been found regarding the antipsychotic dosage and the SRI-treatment duration before the augmentation.
© Georg Thieme Verlag KG Stuttgart · New York.
- Review A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.[Mol Psychiatry. 2006]Review A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF. Mol Psychiatry. 2006 Jul; 11(7):622-32. Epub 2006 Apr 4.
- Review Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials.[Int J Neuropsychopharmacol. 2013]Review Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials.Dold M, Aigner M, Lanzenberger R, Kasper S. Int J Neuropsychopharmacol. 2013 Apr; 16(3):557-74. Epub 2012 Aug 29.
- A Systematic Review of Evidence-based Treatment Strategies for Obsessive- compulsive Disorder Resistant to first-line Pharmacotherapy.[Curr Med Chem. 2018]A Systematic Review of Evidence-based Treatment Strategies for Obsessive- compulsive Disorder Resistant to first-line Pharmacotherapy.Albert U, Marazziti D, Di Salvo G, Solia F, Rosso G, Maina G. Curr Med Chem. 2018; 25(41):5647-5661.
- Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762].[BMC Psychiatry. 2005]Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762].Carey PD, Vythilingum B, Seedat S, Muller JE, van Ameringen M, Stein DJ. BMC Psychiatry. 2005 Jan 24; 5:5. Epub 2005 Jan 24.
- Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.[JAMA Psychiatry. 2013]Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.Simpson HB, Foa EB, Liebowitz MR, Huppert JD, Cahill S, Maher MJ, McLean CP, Bender J Jr, Marcus SM, Williams MT, et al. JAMA Psychiatry. 2013 Nov; 70(11):1190-9.
- Efficacy of antipsychotic augmentation therapy in treatment-resistant obsessive-...Efficacy of antipsychotic augmentation therapy in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomised, placebo-controlled trials - Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews
- MIR423 [Macaca mulatta]MIR423 [Macaca mulatta]Gene ID:100315260Gene
Your browsing activity is empty.
Activity recording is turned off.
See more...